TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, two part adaptive design phase II trial of Olaparib in
patients with advanced castration resistant prostate cancer.
The trial aims to evaluate the the anti-tumour activity of Olaparib in metastatic castration
resistant prostate cancer, identify molecular signatures of tumour cells in responding and
non-responding patients, and to identify predictive biomarkers of Olaparib response.